Skip to main content

My account

Boston Scientific accounts are for healthcare professionals only.

Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.

My Boston Scientific account

Access your online applications and manage your customer profile.

Manage my Boston Scientific account

Quick Links

Contact a representative
Online education and training
Order products online
Reimbursement resources
Return a product
Customer support

Call customer care

1 (888) 272-1001

Internal view of patient's torso demonstrating targeted accuracy of TheraSphere Y-90 Glass Microspheres in liver.

TheraSphere™ Y-90 Glass Microspheres

1,000 patient study

Institutional decision to adopt Y90 as a primary treatment for HCC informed by a 1,000-patient 15-year experience

15 year, 1,000 patient cohort treated with TheraSphere showed benefit vs. standard of care.

Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y90 as primary treatment for HCC informed by a 1,000-patient 15-year experience. Hepatology. 2017 Dec 1.

Filename
TheraSphere_1000_patient_summary_PI-789903-AB.pdf
Size
633 KB
Format
application/pdf
Download 1,000 patient study data
See full manuscript

Overview

  • Locoregional (LRT) therapies such as ablation, TACE and TARE with Yttrium-90 (Y-90) are treatment options for HCC patients who are not eligible for curative resection or outside transplant criteria1,2
  • TARE has become an increasingly accepted alternative to TACE. With the addition of TARE to the BCLC algorithm3, the authors evaluated the outcomes of TARE across all BCLC disease stages:
    • BCLC A: successful downstaging of tumors to liver transplant, hypertrophy of the future liver remnant for potential resection, treats recurrences following resection, significantly prolongs time to progression compared with TACE and represents an alternative to ablation for unablatable lesions4-7
    • BCLC B*: comparable survival yet superior quality of life compared to TACE8,9
    • BCLC C: applicable in patients with portal vein thrombosis,* minimizing the risk of ischemic hepatitis10

*The safety and effectiveness of TheraSphere in patients with HCC tumors involving the portal vein have not been established.

Objective

  • To report data from an institution’s 15-year, 1,000-patient experience that led to an institutional decision to adopt Y-90 TARE as the primary transarterial locoregional treatment for HCC.

Methods

 
  • From 2003 to 2017, 1,000 HCC patients were treated with Y-90 glass microspheres as part of a prospective cohort study (the largest single-center cohort conducted) with 1,577 total treatments (median: 1, range: 1-8)
  • Standard pre-treatment angiography and Tc-99m MAA were performed
  • Target dose was 120 Gy for lobar infusions, however practice evolved with the application of radiation segmentectomy and lobectomy and target doses were modified to >190 Gy (potentially curative ablative dose) and 150 Gy, respectively
  • Median dose per treatment was 119 Gy
  • Follow-up included 4 to 6 week post-treatment scans and then subsequently at 2 to 3 month intervals
  • Overall survival (OS) outcomes were reported using censoring and intention-to-treat (ITT) methodologies

Baseline characteristics

Baseline characteristics ECOG 0 (56%); 1(40%); 2(4%); Child-Pugh A(51%); B(45%); C(4%); BCLC A(26%); B(15%); C(44%); D(4%).

Results

  • Survival for BCLC stages A–C patients treated with Y-90 (47, 25 and 15 months, respectively) compared favorably with survival expectations of BCLC A (36–50 months), BCLC B (18–26 months) and BCLC C (11 months) cited by EASL-EORTC guidelines
  • Properly selected BCLC D patients may benefit from selective Y-90 glass therapy followed by liver transplantation**
  • Overall, 49 (5%) patients developed new grade 3/4 albumin toxicities and 110 (11%) showed grade 3/4 bilirubin toxicities for all Child-Pugh classes
  • No patient developed radiation pneumonitis or gastritis
Table with values for BCLC Stage, Child-Pugh (CP) Score, Median OS [Censored] (months), P-value, Median OS [ITT] (months), P-value.
  • Multivariate models confirmed baseline bilirubin, albumin, ascites, vascular invasion, metastases, distribution, performance status, alpha-fetoprotein (AFP) <100 and index tumor < 5 cm to be significant predictors of survival
  • Survival was not affected by hepatitis C virus status
  • Overall cohort mortality within 30 days of treatment was 1.6% (n=16)

**Off label use

Conclusions

  • Northwestern University adopted Y-90 glass microsphere therapy as their first line transarterial locoregional therapy for liver-only HCC compared to TACE because it allows for fewer treatments, longer time to progression and has demonstrated versatile application as a neoadjuvant to surgical intervention or definitive treatment in all BCLC and Child-Pugh stages
  • Their decision was informed by prospectively collected and incrementally reported outcomes over 15 years
  • Moving Y-90 earlier in the disease care continuum may improve overall HCC outcomes
  • Study Strengths: Largest single-center prospective cohort of HCC patients treated with Y-90 glass microspheres, sample size and follow-up permitted meaningful analyses that compensate for heterogeneity of lesion size and liver function
  • Study Limitations: Single-center study, overestimation of survival in advanced HCC attributed by ECOG 1

TACE= transarterial chemoembolization ; TARE= transarterial radioembolization ; HCC= hepatocellular carcinoma ; BCLC= Barcelona Clinic Liver Classification ; ECOG= Eastern Cooperative Oncology Group ; EASL= European Association for the Study of the Liver ; EORTC= European Organization for Research and Treatment of Cancer

  1. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943. 
  2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines); Hepatobiliary Cancers. In; 2016. 
  3. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2021;S0168-8278(21)02223-6. doi:10.1016/j.jhep.2021.11.018. 
  4. Vouche M, Habib A, Ward TJ et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: Multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 2014;60:192-201. 
  5. Lewandowski RJ, Kulik LM, Riaz A et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009; 9:1920-1928.
  6. Ali R, Riaz A, Gabr A et al. Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection. Eur J Nucl Med Mol Imaging 2017. 
  7. Salem R, Gordon AC, Moulil S et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2016;151:1155-1163.e1152. 
  8. Salem R, Gilbertsen M, Butt Z et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroentrol Hepatol 2013;11:1358-1365.e1351. 
  9. Gabr A, Kallini JR, Gates VL et al. Same-day 90Y radioembolization: implementing a new treatment paradigm. Eur J Nucl Med Mol Imaging 2016;43:2353-2359. 
  10. Sato K, Lewandwoski RJ, Bui JT et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006;29:522-529.

TheraSphere is a registered trademark of Theragenics Corporation used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation.